Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of NA-921 (Bionetide) for the Treatment of Girls and Women with Rett Syndrome

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bionetide (Primary)
Indications Rett syndrome
Focus Registrational; Therapeutic Use
Sponsors Biomed Industries

Most Recent Events

04 Mar 2025 New trial record
03 Mar 2025 Results presented in the Biomed Industries media release.
03 Mar 2025 According to Biomed Industries media release, results from this study will be presented at the IRSF Rett Syndrome Scientific Conference, June 9-11, 2025, in Boston.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com